Return to University Health's Homepage.

Eric Lawitz, MD

UT Health San Antonio
Schedule an appointment: 210-743-4306
Loading...
Loading...
Specialty
Gastroenterology
Board Affiliation/Certification
American Board Internal Medicine/Gastroenterology
American Board of Internal Medicine/Gastroenterology
Education
University of Illinois at Chicago, 1989
Rush Medical College of Rush University, 1993
Residency
Brooke Army Medical Center-Fort Sam, 1996
Fellowships
Brooke Army Medical Center-Fort Sam, 1999
Languages
English
Gender
Male

Texas Liver Tumor Center

7979 Wurzbach Road
Ste 219, Urschel Bldg
San Antonio,TX 78229

University Hospital

4502 Medical Drive
San Antonio,TX 78229

Accepting new patients at this location?

Insurance Accepted
6 Degrees - Transplant
90 Degree Benefits - Commercial
Aetna - EPO
Aetna - PPO/HMO/MC Advantage
Aetna - Transplant
Aetna Better Health - Medicaid-CHIP
Aetna Better Health - Medicaid-STAR
AIG - Transplant
Amerigroup - Medicaid-CHIP
Amerigroup - Medicaid-CHIP Perinate
Amerigroup - Medicaid-STAR
Amerigroup - Medicaid-STAR Kids
Amerigroup - Medicaid-STAR PLUS
Amerigroup - Medicare Advantage
Amerigroup - Medicare-Medicaid Duals
Ancira Enterprises - Direct Employer
Blue Cross Blue Shield of Texas - Exchange (BlueAdvantage)
Blue Cross Blue Shield of Texas - HMO
Blue Cross Blue Shield of Texas - HPN/EPO (Narrow Network)
Blue Cross Blue Shield of Texas - Medicaid-STAR
Blue Cross Blue Shield of Texas - Medicare Advantage HMO
Blue Cross Blue Shield of Texas - Medicare Advantage PPO
Blue Cross Blue Shield of Texas - Narrow HMO (Blue Essentials)
Blue Cross Blue Shield of Texas - Narrow HMO (Blue Premier)
Blue Cross Blue Shield of Texas - PPO
Blue Cross Blue Shield of Texas - Traditional
Blue Cross Blue Shield of Texas - Transplant Programs
Care Improvement Plus - Medicare Advantage-SNP
Cenpatico - Medicaid-CHIP
Cenpatico - Medicaid-STAR
Cenpatico - Medicaid-STAR Health (Foster Care)
Cenpatico - Medicare Advantage
Community First Health Plans - Exchange (EPO)
Community First Health Plans - HMO
Community First Health Plans - Medicaid-CHIP
Community First Health Plans - Medicaid-CHIP Perinate
Community First Health Plans - Medicaid-STAR
Community First Health Plans - Medicaid-STAR Kids
Community First Health Plans - Medicare Advantage HMO
Coventry - HMO
Coventry - PPO
Coventry - Work Comp / Auto
Decent Health Plan - Commercial EPO
EBSO - TPA
Entrust - TPA
FirstCare (Part of Scott & White Health Plans) - Medicaid-STAR
Healthsmart - PPO
Humana - Commercial Behavioral Health
Humana - Exchange (HMOx)
Humana - HMO
Humana - Medicare Advantage Behavioral Health
Humana - Medicare Advantage HMO (Gold)
Humana - Medicare Advantage PPO
Humana - National Transplant Network
Humana - PPO
Humana Military - TRICARE
Imperial Health Plan - Medicare Advantage
Independent Medical Systems (IMS) - PPO
Interlink - Transplant
LifeTrac - Transplant
Magellan - Commercial and Medicaid Behavioral Health
Molina - Commercial Exchange
Molina - Medicaid-CHIP
Molina - Medicaid-CHIP Perinate
Molina - Medicaid-STAR
Molina - Medicare Advantage
Molina - Medicare-Medicaid Duals
OptumHealth - Transplant
Point Comfort Underwriters (PCU) - Refugee Medical Assistance
Point Comfort Underwriters (PCU) - Unaccompanied Children
Preferred Provider Health Plan (PPHP) - Medicare Advantage I-SNP
Prime Health Services - Medicare Advantage
Prime Health Services- PPO
ProCare Advantage - Medicare Advantage I-SNP
Scott & White Health Plan - HMO
Scott & White Health Plan - Medicare Advantage
Scott & White Health Plan - PPO
Superior HealthPlan - Medicaid
Superior HealthPlan - Medicaid-CHIP
Superior HealthPlan - Medicaid-CHIP Perinate
Superior HealthPlan - Medicaid-STAR Health (Foster Care)
Superior HealthPlan - Medicaid-STAR Kids
Superior HealthPlan - Medicaid-STAR PLUS
Superior HealthPlan - Medicare Advantage (Allwell)
Superior HealthPlan - Medicare-Medicaid Duals (Allwell)
Texas Independence Health Plan - Medicare Advantage I-SNP
Three Rivers Provider Network - PPO
TriWest (via BCBSTX) - VA CCN Program
UnitedHealthcare - Medicaid-STAR
UnitedHealthcare - Medicaid-STAR Kids
UnitedHealthcare - Medicaid-STAR PLUS
UnitedHealthcare - Medicare Advantage
UnitedHealthcare - PPO
University of Incarnate Word - Direct Employer
WellCare - Medicare Advantage
WellMed - Medicare Advantage
Please contact your health insurance company to confirm provider participation. For billing and insurance questions, please call our Billing Department at 210-358-3260.
Please contact your health insurance company to confirm provider participation. For billing and insurance questions, please call our Billing Department at 210-358-3260.
I am Vice President of Scientific and Research Development and founder of the Texas Liver Institute. Prior to joining Texas Liver Institute, I spent 11 years at Brooke Army Medical Center in the Department of Gastroenterology and Hepatology, where I served in many teaching and academic positions.
Research Interests:
I have conducted extensive research in hepatology, authored over 300 publications and presented my work at both national and international medical meetings. I am internationally recognized for my work in liver disease research and teaching.
I also serve as a Clinical Professor of Medicine at UT Health San Antonio and attend outpatient clinics.

Journal Articles

  1. Wong VW, Tak WY, Goh GBB, Cheng PN, Lawitz EJ et al,.Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic whites in the STELLAR trials. Clin Gastroenterol Hepatol. 2022 Jan 21:S1542-3565(22)00069-6. doi: 10.1016/j.cgh.2022.01.015.
  2. Lawitz EJ, Bhandari BP, Ruane PJ et al,.Fenofibrate mitigates hypertriglyceridemia in nonalcoholic steatohepatitis patients treated with cilofexor/firsocostat. Clin Gastroenterol Hepatol. 2022 Jan 6:S1542-3565(22) 00002-7. doi: 10.1016/j.cgh.2021.12.044..
  3. Ratziu V, Rinella ME, Neuschwander-Tetri BA, Lawitz E, .et al EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. J Hepatol. 2021 Nov 3: S0168-8278 (21)02155-3. doi: 10.1016/j.jhep.2021.10.018..
  4. Lawitz EJ, Shevell DE, Tirucherai GS, Du S, Chen W, Kavita U, Coste A, Poordad F, Karsdal M, Nielsen M, Goodman Z, Charles ED. .BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial. Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181..
  5. Sanyal AJ, Anstee QM, Trauner M, Lawitz EL, et al,.Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. Hepatology. 2021 Oct 18. doi: 10.1002/hep.32204..
  6. Zamor PJ, Brown A…Lawitz E, Jacobson IM,.High sustained virologic response rates of glecaprevir/pibrentasvir in patients with dosing interruption or suboptimal adherence. Am J Gastroenterol. 2021 Sep 1; 116(9): 1896-1904. doi: 10.14309/ajg.0000000000001332..
  7. Taylor-Weiner A, Pokkalla H,….Lawitz EJ,.A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH. Hepatology. 2021 Jul; 74(1): 133-147..
  8. Harrison SA, Bashir MR,…Lawitz EJ et al.,.A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis. J Hepatol. 2021 Jul; 75(1): 25-33. doi: 10.1016/j.jhep.2021.01.047. Epub 2021 Feb 11..
  9. Alkhouri N, Reddy GK, Lawitz E,.Oligonucleotide-based therapeutics: an emerging strategy for the treatment of chronic liver diseases. Hepatology. 2021 Apr; 73(4): 1581-1593..
  10. Younossi ZM, Anstee QM,…Lawitz EJ et al,.The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology. 2021 Apr; 160(5): 1608-1619.e13..
  11. Lawitz E, Landis CS, Flamm SL et al.,.Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomized, open-label study. Lancet Gastroenterol Hepatol. 2020 Oct; 5(10): 918-926..
  12. Younossi ZM, Wong VW, Anstee QM,…Lawitz EJ, et al., .Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes. Hepatol Commun. 2020 Aug 28; 4(11): 1637-1650..
  13. Patel K, Harrison SA, Lawitz EJ, et al., .Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled study. Hepatology. 2020 Jul; 72(1): 58-71..
  14. Harrison SA, Wong VW, Lawitz EJ et al.,.Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020 Jul; 73(1): 26-39..
  15. Lawitz E, Poordad F, Gutierrez JA, Beumont M, Beets G, Vandevoorde A, Remoortere PV, Luo D, Vijgen L, Eygen VV, Gamil M. .Simeprevir, daclatasvir, and sofosbuvir for hepatitis C virus-infected patients: Long-term follow-up results from the open-label, Phase II IMPACT study. Health Sci Rep. 2020 Feb 22;3(2): e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun..
  16. Lawitz E, Flisiak R et al.,.Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. Liver Int. 2020 May; 40(5): 1032-1041..
  17. Garcia-Tsao G, Bosch J, Lawitz EJ, et al.,.Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020 May; 72(5): 885-895..
  18. Bajaj JS, Bloom PP,Lawitz E,.Variability and lability of ammonia levels in healthy volunteers and patients with cirrhosis: implications for trial design and clinical practice. Am J Gastroenterol. 2020 May; 115(5): 783-785..
  19. Younossi ZM, Anstee QM,…Lawitz EJ et al, .The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis. Gastroenterology. 2021 Apr; 160(5): 1608-1619.e13..
  20. Singh A, Gosai F, Siddiqui MT, Gupta M, Lopez R, Lawitz E, Poordad F, Carey W, McCullough A, Alkhouri N. .Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients with Type-2 Diabetes with Biopsy-proven Nonalcoholic Fatty Liver Disease. J Clin Gastroenterol. 2020 Mar 11. doi: 10.1097/MCG.0000000000001339. [Epub ahead of print] PMID:32168133.
  21. Khoudari G, Singh A, Noureddin M, Fritze D, Lopez R, Asaad I, Lawitz E, Poordad F, Kowdley KV, Alkhouri N. .Characterization of patients with both alcoholic and nonalcoholic fatty liver disease in a large United States cohort. World J Hepatol. 2019 Oct 27;11(10):710-718. doi: 10.4254/wjh.v11.i10.710..
  22. Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F. .Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients. World J Gastroenterol. 2019;25(18):2229-2239..
  23. Loo N, Hanysak B, Mann J, Ramirez R, Kim J, Mitchell R, Van Frank T, Guerrero R, Hinojosa K, Christensen K, Pedicone LD, Alkhouri N, Wells J, Landaverde C, Rodas F, Lawitz E, Poordad F. .Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance. Medicine (Baltimore). 2019;98(26): e16254.
  24. Lawitz E, Poordad F., Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW. .Efficacy and safety of ruzasvir 60 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4 or 6 infection. J Viral Hepat. 2019 Jun; 26(6): 675-684. doi: 10.1111/jvh.13079..
  25. Lawitz EJ, Coste A, Poordad F, Alkhouri N, Loo N, McColgan BJ, Tarrant JM, Nguyen T, Han L, Chung C, Ray AS, McHutchison JG, Subramanian GM, Myers RP, Middleton MS, Sirlin C, Loomba R, Nyangau E, Fitch M, Li K, Hellerstein M..Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients with Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2018 Dec;16(12):1983-1991.
  26. Singh A, Fritze D, Mansouri M, Lopez R, Poordad F, Lawitz E, Cigarroa F, Halff G, Alkhouri N. .Characteristics and Outcomes of Liver Transplantation for Primary Biliary Cholangitis (PBC) in Young patients: Analysis of the United Network for Organ Sharing Database. Transplantation. 2018 Oct 30. doi: 10.1097/TP.0000000000002501. [Epub ahead of print].
  27. Alkhouri N, Poordad F, Lawitz E..Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes. Hepatol Commun. 2018 Jun 7;2(7):778-785.
  28. Alkhouri N, Lawitz E, Poordad F. .Novel treatments for chronic hepatitis C: closing the remaining gaps. Curr Opin Pharmacol. 2017 Nov 6; 37:107-111. doi: 10.1016/j.coph.2017.10.001. [Epub ahead of print]..
  29. Poordad F, Lawitz E, Gutierrez JA, Guerrero J, Speeg K, Swenson ES..An HCV-positive recipient of an HCV-positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin. Clin Case Rep. 2017 Feb 3;5(4):371-375..
  30. Lawitz E, Poordad F, Wells J, Hyland RH, Yang Y, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Landaverde C, Gutierrez J. .Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in DAA-experienced patients with genotype 1 HCV. Hepatology. 2017 Feb 21. doi: 10.1002/hep.29130. [Epub ahead of print].
  31. Lawitz E, Poordad F, Gutierrez JA, Kakuda TN, Picchio G, Beets G, Vandevoorde A, Van Remoortere P, Jacquemyn B, Luo D, Ouwerkerk-Mahadevan S, Vijgen L, Van Eygen V, Beumont M..Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease. J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645. [Epub ahead of print].
  32. Owens CM, Brasher BB, Polemeropoulos A, Rhodin MH, McAllister N, Peng X, Wang C, Ying L, Cao H, Lawitz E, Poordad F, Rondon J, Box TD, Zeuzem S, Buggisch P, Lin K, Qiu YL, Jiang L, Colvin R, Or YS..Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239. Antimicrob Agents Chemother. 2016;60(10):6207-15. doi: 10.1128/AAC.00808-16. Print 2016 Oct..
  33. Lawitz E, Poordad F, Hyland RH, Wang J, Liu L, Dvory-Sobol H, Brainard DM, McHutchison JG, Gutierrez JA. .Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies. Antivir Ther. 2016 Jun 27. doi: 10.3851/IMP3062. [Epub ahead of print].
  34. Gutierrez JA, Lawitz EJ, Poordad F. .Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J Viral Hepat. 2015;22(11):861-70..
  35. Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. .Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology. 2015;61(3):769-75.
  36. Lawitz E, Sullivan G, Rodriguez-Torres M, Bennett M, Poordad F, Kapoor M, Badri P, Campbell A, Rodrigues L Jr, Hu Y, Pilot-Matias T, Vilchez RA. .Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection. J Infect. 2015;70(2):197-205.
  37. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, DeJesus E, Pearlman B, Rabinovitz M, Gitlin N, Lim JK, Pockros PJ, Scott JD, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay KL, Beumont M, Jacobson IM.Lancet. .Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
  38. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P, Foster GR, Sulkowski MS, Xie W, Pilot-Matias T, Liossis G, Larsen L, Khatri A, Podsadecki T, Bernstein B..Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014;370(3):222-32.
  39. Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, Nyberg LM, Lee WM, Schiff E, Long J, Noviello S, Brass CA, Pedicone LD, Sulkowski MS. .Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: Results of the IDEAL study. Clin Infect Dis. 2014;58(7):960-9..
  40. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. ION-3 Investigators. N Engl J Med. 2014 May 15;370(20):1879-88..
  41. Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, Yoshida EM, Galati J, Luketic V, McCone J, Jacobson I, Marcellin P, Muir AJ, Poordad F, Pedicone LD, Albrecht J, Brass C, Howe AY, Colvard LY, Helmond FA, Deng W, Treitel M, Wahl J, Bronowicki JP. .Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response. J Hepatol. 2014;60(4):748-56..
  42. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P;.Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. ION-2 Investigators. N Engl J Med. 2014 Apr 17;370(16):1483-93..
  43. Lawitz E, Poordad FF, Pang P, Hyland R, Ding X, Mo H, Symonds W, McHutchison J,.Membreno F. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-23..
  44. Afdhal NH, Dusheiko GM, Giannini EG, Chen PJ, Han KH, Mohsin A, Rodriguez-Torres M, Rugina S, Bakulin I, Lawitz E, Shiffman ML, Tayyab GU, Poordad F, Kamel YM, Brainsky A, Geib J, Vasey SY, Patwardhan R, Campbell FM, Theodore D.. Eltrombopag Increases Platelet Numbers in Thrombocytopenic Patients with HCV Infection and Cirrhosis, Allowing for Effective Antiviral Therapy. Gastroenterology. 2014;146(2):442-52..
  45. Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ. .Boceprevir Plus Peginterferon α-2b/Ribavirin in Chronic Hepatitis C Genotype 1: Impact of Baseline Viral Load on Sustained Virologic Response. J Clin Gastroenterol. 2014;48(5):435-43..
  46. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. AI444040 Study Group.N Engl J Med. 2014 Jan 16;370(3):211-21..
  47. Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson D, Rossaro L, Balart L, Morgan T, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS..Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients with Chronic HCV Genotype 1 Infection-a Randomized Trial. Gastroenterology 2013;145(5):1035-1044..
  48. Gordon SC, Yoshida EM, Lawitz EJ, Bacon BR, Sulkowski MS, Davis M, Poordad F, Bronowicki JP, Esteban R, Sniukiene V, Burroughs MH, Deng W, Dutko FJ, Brass CA, Albrecht JK, Rajender Reddy K. .Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther. 2013 Jul;38(1):16-27.
  49. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Lancet..Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. 2013 Jun 15;381(9883):2100-7..
  50. Lawitz E, Poordad F, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, .Bernstein A Phase 2a Trial of 12-Week Interferon-Free Therapy with Two Direct-Acting Antivirals (ABT-450/r, ABT-072) and Ribavirin in IL28B C/C Patients with Chronic Hepatitis C Genotype 1. J Hepatol. 2013;59(1):18-23..
  51. Poordad F, Lawitz E, Kowdley K, Cohen D, Podsacki T, Siggelkow S, Heckaman M, Larsen L, Menon R, Koev G, Tripathi R, Pilot-Matias T, Bernstein B. .Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C. N Engl J Med 2013;368:45-53.
  52. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Tarek Al-Assi M, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. .Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options. N Engl J Med. 2013 May 16; 368 (20):1867-77. .
  53. Janssen HLA, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, Van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR..Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med. 2013 May 2; 368(18):1685-94..
  54. Flamm SL, Lawitz E, Jacobson I, Bourlière M, Hezode C, Vierling JM, Bacon BR, Niederau C, Sherman M, Goteti V, Sings HL, Barnard RO, Howe JA, Pedicone LD, Burroughs MH, Brass CA, Albrecht JK, Poordad F. .Boceprevir With Peginterferon Alfa-2a-Ribavirin Is Effective for Previously Treated Chronic Hepatitis C Genotype 1 Infection. Clin Gastroenterol Hepatol. 2013;11(1):81-87.
  55. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, Afdhal NH, Bernstein DE, Dejesus E, Freilich B, Nelson DR, Dieterich DT, Jacobson IM, Jensen D, Abrams GA, Darling JM, Rodriguez-Torres M, Reddy KR, Sulkowski MS, Bzowej NH, Hyland RH, Mo H, Lin M, Mader M, Hindes R, Albanis E, Symonds WT, Berrey MM, Muir A. .Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-8..
  56. Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, Zhu Q, Urban TJ, Patel K, Tillmann HL, Naggie S, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, King JW, Kwo PY, Shianna KV, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Goldstein DB, McHutchison JG, Muir AJ..Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol. 2012 Feb;56(2):313-9..
  57. Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee P, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C..Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1 Lok AS. N Engl J Med. 2012 Jan 19; 366(3):216-24..
  58. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team..Telaprevir for retreatment of HCV infection. N Engl J Med. 2011 Jun 23;364(25):2417-28..
  59. Bacon BR; Gordon SC; Lawitz E; Marcellin P; Vierling JM; Zeuzem S; Poordad F; Boparai N; Burroughs M; Brass CA; Albrecht JK; Esteban R..Boceprevir for Treatment of Chronic Hepatitis C Genotype 1 Nonresponders. N Engl J Med. 2011; 364:1207-1217..
  60. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK; SPRINT-1 investigators..Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28;376(9742):705-16..
  61. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team..Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology. 2010;139(4):1257-66.
  62. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R, Poordad F, Lawitz EJ, McCone J, Shiffman ML, Galler GW, Lee WM, Reindollar R, King JW, Kwo PY, Ghalib RH, Freilich B, Nyberg LM, Zeuzem S, Poynard T, Vock DM, Pieper KS, Patel K, Tillmann HL, Noviello S, Koury K, Pedicone LD, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG..IL28B Polymorphism Improves Viral Kinetics and Is the Strongest Pre-treatment Predictor of SVR in HCV-1 Patients. Gastroenterology. 2010;139(1):120-9..
  63. Poordad F, Lawitz E, Shiffman ML, Hassanein T, Muir AJ, Bacon BR, Heise J, Halliman D, Chun E, Hammond J..Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology. 2010;52(4):1208-15.
  64. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team..Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580-93..
  65. Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination (METRO) study group. .Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders. Hepatology. 2009;50(6):1719-26.
  66. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS; IDEAL Study Team. .Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361(6);580-93..
Call 210-743-4306 to request an appointment with this doctor.
Patient reviews

    Download Our Mobile App

    Access health information, get turn-by-turn navigation in University Hospital, find a doctor or location, and more.